Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells

This publication has 77 references indexed in Scilit:

• Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling
  International Immunopharmacology, 2022
• Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
  European Journal of Immunology, 2021
• Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
  Cell Reports, 2018
• Sirolimus and everolimus in kidney transplantation
  Drug Discovery Today, 2015
• Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study
  Leukemia Research, 2012
• Overview of tacrolimus-based immunosuppression after heart or lung transplantation
  The Journal of Heart and Lung Transplantation, 2005
• The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo
  Journal of Immunological Methods, 2004
• A Putative Sirolimus (Rapamycin) Effector Protein
  Biochemical and Biophysical Research Communications, 1994
• Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G₁ phase of the cycle
  Journal of Cellular Physiology, 1993
• The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.
  The EMBO Journal, 1990